A Phase 2 interventional study of Part A: RPL554 and Part B: RPL554 in Pulmonary Disease, Chronic Obstructive, sponsored by Verona Pharma plc. Completed at 1 site in United States. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2022-09-26.
Sponsored by Verona Pharma plc (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc — 1 open to participants now, 3 under way, 1 of them phase 3. Pulmonary Disease, Chronic Obstructive · Merck & Co., Inc.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, this one is the 19th largest by enrollment, is one of 2 that started in 2018, is one of 18 in phase 2, and was the 15th registered.
5,527 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.
Browse Pulmonary Disease, Chronic Obstructive studies →1 of the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc is open now, in 1 country. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in United States
Ages 40–80
By country, each count listing its studies:
Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.
This study: 40 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 37 is below the median of 62 across 3,847 interventional studies indexed under Pulmonary Disease, Chronic Obstructive.
Median enrollment 89 across the 26 interventional studies. Of the 23 that completed or were terminated, 15 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Verona Pharma plc, one of the names counted as Merck & Co., Inc. Under that name alone:
Verona Pharma plc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.
1 of the studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05270525Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USAEffect of Ensifentrine (MK-5884/RPL554) on Sputum Markers of Inflammation in Chronic Obstructive Pulmonary Disease (COPD) (MK-5884-023/RPL554-CO-207) | 2027-03-01 |
Add it to your calendar (.ics) → With an account.
Among the 26 studies in Pulmonary Disease, Chronic Obstructive by Merck & Co., Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by dry powder inhaler (DPI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
The study will consist of two parts. Part A is a parallel group, placebo-controlled single dose study to ascertain the Pharmacokinetics (PK) profile, safety and bronchodilator effect of RPL554 administered via dry powder inhaler (DPI). Five of the 6 treatment arms will be double-blind and one will be single-blind (due to the different number of capsules administered). Part B is a placebo-controlled, complete block cross-over, repeat dose study to assess the bronchodilator effect of repeat doses of RPL554 delivered via a DPI.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Post-bronchodilator (four puffs of albuterol) spirometry at Screening demonstrating the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo controlled, parallel group single dose. Five of the 6 treatment arms will be double-blind and one will be single-blind
Drug: Part A: RPL554 · Drug: Placebos
Double-blind, placebo-controlled, complete block cross-over
Drug: Part B: RPL554 · Drug: Placebos
1 dose of either 50mcg/100mcg/1500mcg/3000mcg/6000mcg or placebo via dry powder inhaler
Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A
Part A: 1 dose of either 50ncg/100ncg/1500ncg/3000ncg/6000ncg or placebo via dry powder inhaler. Part B: Patients will receive 4 or 5 repeat dose treatments in crossover fashion - doses will be confirmed after Part A.
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12)
RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose
Time frame: Day 1
Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t)
RPL554 Area under the curve at maximum concentration after a single dose
Time frame: Day 1
Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life)
RPL554 Plasma pharmacokinetics Half-life concentration after a single dose
Time frame: Day 1
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7
Time frame: Day 7
Part A: Change From Baseline in Average FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Part A: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose
Time frame: Day 1
Part A: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose
Time frame: Day 1
Part A: Safety and Tolerability / Hematology Safety Assessments
number of patients with treatment-emergent hematology abnormal laboratory assessments
Time frame: Day 1
Part A: Safety and Tolerability / Blood Chemistry Safety Assessments
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Time frame: Day 1
Part A: Safety and Tolerability / Urinalysis Safety Assessments
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: Day 1
Part A: Safety and Tolerability / Supine Vital Signs - Pulse Rate
Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose
Time frame: Day 1
Part A: Safety and Tolerability / Supine Vital Signs - Blood Pressure
number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp)
Time frame: Day 1
Part A: Safety and Tolerability / ECG - QTcF
number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Time frame: Day 1
Part A: Safety and Tolerability / ECG - Heart Rate
number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm
Time frame: Day 1
Part B: Change From Baseline in Average FEV1 (Over 4 Hrs)
Change from baseline in average FEV1 (over 4 hours) on Day 7
Time frame: Day 7
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7
Time frame: Day 7
Part B: Change From Baseline in Trough FEV1
Change from Baseline FEV1 to Morning Trough FEV1 on Day 7
Time frame: Day 7
Part B: Change From Baseline in Peak FEV1 (Over 4 Hours)
Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose
Time frame: Day 1
Part B: Change From Baseline in Average FEV1 (Over 4 Hours)
Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1
Time frame: Day 1
Part B: Change From Baseline in Average FEV1 (Over 12 Hours)
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1
Time frame: Day 1
Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action)
Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1
Time frame: Day 1
Part B: Safety and Tolerability / Hematology Safety Assessments
number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group).
Time frame: Day 7
Part B: Safety and Tolerability / Blood Chemistry Safety Assessments
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).
Time frame: Day 7
Part B: Safety and Tolerability / Urinalysis Safety Assessments
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Time frame: Day 7
Part B: Safety and Tolerability / ECG - QTcF
number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec
Time frame: Day 7
Part B: Safety and Tolerability / ECG - Heart Rate
number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Time frame: Day 7
Part B: Safety and Tolerability / Supine Vital Signs - Pulse Rate
number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20
Time frame: Day 7
Part B: Safety and Tolerability / Supine Vital Signs - Blood Pressure
number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20)
Time frame: Day 7
Part B: Change From Baseline in Peak Pulse Rate (Day 1)
Change from baseline in peak pulse after first dose on Day 1
Time frame: Day 1
Part B: Change From Baseline in Peak Pulse Rate (Day 7)
Change from baseline in peak pulse after morning dosing on Day 7
Time frame: Day 7
Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax)
RPL554 steady-state PK (tmax) after morning dose on Day 7
Time frame: Day 7
Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax)
RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7
Time frame: Day 7
Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h)
RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7
Time frame: Day 7
37 subjects enrolled for Part A and anticipated to continue into Part B.
| Milestone | 0.15 mg/Part A | 0.50 mg/Part A | 1.5 mg/Part A | 3 mg/Part A | 6 mg/Part A | Placebo/Part A | Seq. 1/Part B | Seq. 2/Part B | Seq. 3/Part B | Seq. 4/Part B | Seq. 5/Part B | Seq. 6/Part B | Seq. 7/Part B | Seq. 8/Part B | Seq. 9/Part B | Seq. 10/Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 6 | 6 | 7 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 6 | 6 | 7 | 6 | 6 | 6 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | 0.15 mg/Part A | 0.50 mg/Part A | 1.5 mg/Part A | 3 mg/Part A | 6 mg/Part A | Placebo/Part A | Seq. 1/Part B | Seq. 2/Part B | Seq. 3/Part B | Seq. 4/Part B | Seq. 5/Part B | Seq. 6/Part B | Seq. 7/Part B | Seq. 8/Part B | Seq. 9/Part B | Seq. 10/Part B |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 3 | 4 | 3 | 4 | 3 | 3 | 4 | 4 | 3 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 1 | 4 | 3 | 4 | 3 | 3 | 4 | 4 | 3 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RPL554 Plasma pharmacokinetics AUC0-12 (Area under the Curve) after single dose
| h*pg/mL | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12) | 260 ± 53.5 | 472 ± 106.7 | 2210 ± 62.3 | 4160 ± 47.2 | 9730 ± 62.3 |
RPL554 Area under the curve at maximum concentration after a single dose
| h*pg/mL | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: RPL554 Plasma Pharmacokinetic Parameter (AUC 0-t) | 222 ± 55.5 | 495 ± 128.2 | 2680 ± 56.5 | 4920 ± 44.5 | 11600 ± 68.3 |
RPL554 Plasma pharmacokinetics Half-life concentration after a single dose
| h | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg |
|---|---|---|---|---|---|
| Part A: RPL554 Plasma Pharmacokinetic Parameter (Half-life) | 3.59 | 5.39 ± 28.7 | 7.48 ± 43.3 | 6.65 ± 33.6 | 6.66 ± 25.4 |
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) on Day 7
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.220 ± 0.1593 | 0.293 ± 0.2411 | 0.298 ± 0.2355 | 0.378 ± 0.2182 | 0.118 ± 0.1437 |
Change from Baseline FEV1 to Average FEV1 (over 4 hours) After Single Dose
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.109 ± 0.0380 | 0.213 ± 0.1226 | 0.326 ± 0.249 | 0.337 ± 0.1831 | 0.334 ± 0.1170 | 0.040 ± 0.0517 |
Change from Baseline FEV1 to Average FEV1 (over 12 hours) After Single Dose
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.045 ± 0.0384 | 0.113 ± 0.1703 | 0.214 ± 0.2172 | 0.243 ± 0.2715 | 0.176 ± 0.0481 | -0.011 ± 0.0749 |
Change from Baseline FEV1 to Peak FEV1 (over 4 hours) After Single Dose
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo |
|---|---|---|---|---|---|---|
| Part A: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.203 ± 0.0646 | 0.298 ± 0.1280 | 0.429 ± 0.2504 | 0.468 ± 0.2135 | 0.452 ± 0.1382 | 0.135 ± 0.0922 |
number of patients with treatment-emergent hematology abnormal laboratory assessments
Results for this outcome have not been posted.
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments
Results for this outcome have not been posted.
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Results for this outcome have not been posted.
Change from Baseline Pulse Rate to Peak Pulse Rate (over 4 hours) After Single Dose
Results for this outcome have not been posted.
number of patients with treatment-emergent abnormal vital signs (blood pressure in mm Hg) (An increase from baseline of \>=20 in systolic bp)
Results for this outcome have not been posted.
number of patients with treatment-emergent abnormal ECG parameters, QTcF in msec
Results for this outcome have not been posted.
number of patients with treatment-emergent clinically significant abnormal ECG parameters, heart rate in bpm
Results for this outcome have not been posted.
Change from baseline in average FEV1 (over 4 hours) on Day 7
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 4 Hrs) | 0.100 ± 0.1430 | 0.176 ± 0.2253 | 0.184 ± 0.2176 | 0.244 ± 0.1953 | 0.017 ± 0.1526 |
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 7
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.052 ± 0.1759 | 0.106 ± 0.2125 | 0.096 ± 0.1796 | 0.163 ± 0.1679 | 0.016 ± 0.1455 |
Change from Baseline FEV1 to Morning Trough FEV1 on Day 7
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Trough FEV1 | -0.036 ± 0.1332 | 0.031 ± 0.1821 | 0.020 ± 0.1838 | 0.030 ± 0.1539 | -0.067 ± 0.1577 |
Change from baseline FEV1 in peak FEV1 (over 4 hours) after first dose
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Peak FEV1 (Over 4 Hours) | 0.310 ± 0.1382 | 0.332 ± 0.2181 | 0.401 ± 0.1705 | 0.404 ± 0.1867 | 0.188 ± 0.1267 |
Change from baseline FEV1 in average FEV1 (over 4 hours) on Day 1
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 4 Hours) | 0.201 ± 0.1180 | 0.227 ± 0.2026 | 0.268 ± 0.1518 | 0.285 ± 0.1597 | 0.079 ± 0.1081 |
Change from baseline FEV1 in average FEV1 (over 12 hours) on Day 1
| L | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | Placebo |
|---|---|---|---|---|---|
| Part B: Change From Baseline in Average FEV1 (Over 12 Hours) | 0.101 ± 0.1314 | 0.139 ± 0.1921 | 0.135 ± 0.1655 | 0.182 ± 0.1536 | 0.044 ± 0.1073 |
Determination of onset of action (\>10% increase in FEV1 from pre- to post-first dose, censored at 120 minutes) on Day 1
| mins | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg |
|---|---|---|---|---|
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Onset of Action) | 13.0 (3 to 120) | 15 (3 to 120) | 15 (4 to 125) | 13 (4 to 120) |
number of patients with treatment-emergent hematology abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 or at the end of study in \>3 patients in each treatment group).
Results for this outcome have not been posted.
number of patients with treatment-emergent blood chemistry abnormal laboratory assessments (changes from normal at baseline to low or high on Day 7 in each treatment group).
Results for this outcome have not been posted.
number of patients with treatment-emergent urinalysis abnormal laboratory assessments
Results for this outcome have not been posted.
number of patients with treatment-emergent clinically significant abnormal ECG parameters, QTcF in msec
Results for this outcome have not been posted.
number of patients with treatment-emergent abnormal ECG parameters, heart rate in bpm
Results for this outcome have not been posted.
number of patients with treatment-emergent abnormal vital signs (pulse rate in bpm) An increase from baseline of \>=20
Results for this outcome have not been posted.
number of patients with treatment-emergent abnormal vital signs (systolic blood pressure in mm Hg) (An increase from baseline of \>=20)
Results for this outcome have not been posted.
Change from baseline in peak pulse after first dose on Day 1
Results for this outcome have not been posted.
Change from baseline in peak pulse after morning dosing on Day 7
Results for this outcome have not been posted.
RPL554 steady-state PK (tmax) after morning dose on Day 7
| h | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg |
|---|---|---|---|---|
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Tmax) | 1.000 (0.417 to 2.000) | 1.000 (0.000 to 3.917) | 1.000 (0.000 to 2.000) | 1.000 (0.000 to 2.000) |
RPL554 steady-state PK (Cmax and accumulation ratio) after morning dose on Day 7
| pg/mL | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg |
|---|---|---|---|---|
| Part B: RPL554 Plasma Pharmacokinetic Parameter (Cmax) | 68.7 ± 41.6 | 237 ± 47.4 | 591 ± 71.1 | 1240 ± 41.4 |
RPL554 steady-state PK (AUC0-12h and accumulation ratio) after morning dose on Day 7
| h*pg/mL | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg |
|---|---|---|---|---|
| Part B: RPL554 Plasma Pharmacokinetic Parameter (AUC0-12h) | 263 ± 56.2 | 1240 ± 52.3 | 3070 ± 73.6 | 6460 ± 49.9 |
Collected over Part A: 24 hours. Part B: Approximately 70 days. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: 0.15 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: 0.50 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: 1.5 mg | 0/7 (0%) | 0/7 (0%) | 1/7 (14.3%) |
| Part A: 3 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: 6 mg | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part A: Placebo | 0/6 (0%) | 0/6 (0%) | 0/6 (0%) |
| Part B: 0.15 mg | 0/35 (0%) | 0/35 (0%) | 3/35 (8.6%) |
| Part B: 0.50 mg | 0/33 (0%) | 0/33 (0%) | 9/33 (27.3%) |
| Part B: 1.5 mg | 0/32 (0%) | 0/32 (0%) | 4/32 (12.5%) |
| Part B: 3 mg | 0/33 (0%) | 0/33 (0%) | 4/33 (12.1%) |
| Part B: Placebo | 0/32 (0%) | 0/32 (0%) | 5/32 (15.6%) |
| Event | Part A: 0.15 mg | Part A: 0.50 mg | Part A: 1.5 mg | Part A: 3 mg | Part A: 6 mg | Part A: Placebo | Part B: 0.15 mg | Part B: 0.50 mg | Part B: 1.5 mg | Part B: 3 mg | Part B: Placebo |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Atrioventricular block first degreeCardiac disorders | 0/6 | 0/6 | 1/7 | 0/6 | 0/6 | 0/6 | 0/35 | 0/33 | 0/32 | 0/33 | 0/32 |
| HypertensionVascular disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 1/35 | 2/33 | 2/32 | 1/33 | 2/32 |
| Blood thyroid stimulating hormone increasedInvestigations | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/35 | 1/33 | 2/32 | 1/33 | 0/32 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/35 | 1/33 | 0/32 | 0/33 | 2/32 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 1/35 | 2/33 | 0/32 | 1/33 | 0/32 |
| Blood creatine phosphokinase increasedInvestigations | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/35 | 1/33 | 0/32 | 1/33 | 1/32 |
| Eye contusionInjury, poisoning and procedural complications | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/35 | 1/33 | 0/32 | 0/33 | 0/32 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 0/35 | 1/33 | 0/32 | 0/33 | 0/32 |
| Ear infectionInfections and infestations | 0/6 | 0/6 | 0/7 | 0/6 | 0/6 | 0/6 | 1/35 | 0/33 | 0/32 | 0/33 | 0/32 |
| Age, Continuous(years) | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 61.7 ± 10.15 | 58.3 ± 3.56 | 63.7 ± 6.68 | 52.7 ± 3.88 | 59.3 ± 7.81 | 60.8 ± 8.80 | 59.5 ± 7.57 |
| Sex: Female, Male(Participants) | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 4 | 5 | 3 | 5 | 2 | 4 | 23 |
| Male | 2 | 1 | 4 | 1 | 4 | 2 | 14 |
| Race (NIH/OMB)(Participants) | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 2 | 0 | 0 | 0 | 2 |
| White | 6 | 6 | 5 | 6 | 6 | 6 | 35 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | 0.15 mg | 0.50 mg | 1.5 mg | 3 mg | 6 mg | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 6 | 6 | 7 | 6 | 6 | 6 | 37 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2018 to primary completion in May 2019, 5 months.
Results were first posted in May 2021, 1 year 11 months after primary completion.
Of 120 industry-sponsored phase 2 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 5 months is below that.
Counting every sponsor, half of 167 studies reached it within 17 months; a quarter within 10 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pulmonary Disease, Chronic Obstructive →